

## **Alain Stricker-Krongrad, PhD**

### **President and Chief Scientific Officer**

#### **BIOMEDICAL RESEARCH MODELS/BIOMERE**

#### **EDUCATION:**

- 1993 **Ph.D.** Pharmacology, INSERM, University of Nancy, France  
 Advisor: Dr. B.Beck. *Thesis title "Central role of neuropeptide Y"*  
**Distinction:** Magna Cum Laudae
- 2001 **Post-graduate Training:** Clinical Pharmacology, Drug Development and Regulation. Tufts Center for the Study of Drug Development. Tufts University.
- 2002 **Project Management Training:** Leading Project Teams in Pharmaceutical R&D Tufts Center for the Study of Drug Development and Beacon Hill Technologies. Tarrytown, NY
- 2002 **Project Management Training:** Management of Technological Change Massachusetts Institute of Technology Cambridge, MA
- 2003 **FDA Regulation Training:** The Mechanics of Preparing INDs and NDAs CFPA East Brunswick, NJ

#### **PROFILE:**

- ✓ Successfully carried pharmaceutical and medical product (synthetics and devices) from pre-formulation and conception through nonclinical development to clinical trials (I.N.D./C.T.A. and I.D.E.)
- ✓ Successfully carried biological products (therapeutic proteins and cell-based products) from discovery through preclinical development to clinical trials (I.N.D. and C.T.A.)
- ✓ Demonstrated capacity to meet aggressive timelines for the delivery of therapeutic candidates to clinical status.
- ✓ Comprehensive understanding of pharmaceutical and medical research and development.
- ✓ Broad-based background including cell and molecular pharmacology, disease-based animal models development, drug metabolism, animal and human pharmacokinetics, and toxicology.
- ✓ Broad-based Animal Pharmacology and Toxicology background including rodents, canines and non-human primates.
- ✓ Comprehensive experience in Efficacy and Safety Assessments and Clinical Pharmacology.
- ✓ Comprehensive knowledge of FDA/EMEA/ICH regulatory guidances and GLP guidelines .
- ✓ Demonstrated organizational, communication, publication and writing skills.
- ✓ Fluent in English, French and German.

**PROFESSIONAL AFFILIATIONS:**

- American College of Toxicology
- North American Academy of Clinical Toxicology
- American College of Clinical Pharmacology
- Safety Pharmacology Society
- American Psychological Association / Division 6
- Society for Neuroscience

**EXPERIENCE :****Biomedical Research Models and Biomere**

*2010 (Nov)-Present President and Chief Scientific Officer*

- **Senior Scientific Leadership:** Providing senior scientific leadership and scientific oversight through management of all functional scientific areas. Identifying key science-based issues needing discussion at the appropriate meeting venue and contributing exemplary leadership in determining advancement of scientific programs.
- **Scientific Development:** In charge of identifying and fostering science-related initiatives and capabilities. Recommending and developing new technologies, techniques and/or cross-functional contract research services. Developing and maintaining client/sponsor relationships.
- **Business Development:** Identifying and evaluating new capabilities to expand the revenue base of the company. Providing a focal point for assessing client-related program needs and proposals for improvement and effect their implementation within the Company.
- **Strategic Business Leadership:** Developing short- and long-term strategic plans regarding capital investment, new technologies and services, and scientific staffing and facilities as they relate to the global expansion of the Company.

**Charles River Laboratories, Preclinical Services**

*2008 (March)-2010(Nov) Chief Scientific Officer*

- **Senior Scientific Leadership:** Provided senior scientific leadership and represented Preclinical Services as a member of senior executive management. Contributed to problem resolution of study related science-based issues. Provided Study Directors and other scientists with guidance in the interpretation and reporting of pharmacology and toxicology data.
- **Report and Protocol Scientific Review:** Contributed to the interactions of the Study Directors with Sponsors and provided scientific oversight for study design, preparation of protocols, interpretation of data, and preparation of study reports. Interacted with Study Directors and their Supervisors to ensure study reports of high quality. Provided peer review of study reports.
- **Functional Area(s) of Expertise:** Provided scientific oversight through management of all functional scientific areas. Identified and recommended new technologies, techniques and/or cross-functional management of staff responsible for the specialty area. Worked directly with staff in the functional areas to resolve scientific and technical issues.

- **Preclinical Function:** Participated in global cross-site initiatives related to scientific initiatives, harmonization of procedures, and standardization of templates for protocols and reports. Provided scientific and regulatory advice.
- **Regulatory:** Participated in regulatory consulting by responding to Sponsor requests, such as the development of drug development strategies, placement of non-clinical studies, and compilation of regulatory submissions (INDs and NDAs).
- **Business Development:** Identified and evaluated new capabilities to expand the scientific base of the company. Provided a focal point for assessing client-related program needs and proposals for improvement and effect their implementation at different sites within Preclinical Services.

*2006 (Jan)-2008 (Feb) Senior Director and Head of Preclinical Safety and Pharmacology and Metabolism and Pharmacokinetic Services*

- In charge of Pharmaceutical and Experimental Medicine (P.E.M.) for the non-clinical evaluation (efficacy and safety) of synthetics, biologics, cell-based, devices and surgical products
- In charge of Metabolism and Pharmacokinetics (M.A.P.) for the non-clinical and clinical pharmacological evaluations (metabolism and PK) of synthetics and biologics.
- Directed the execution of pharmacology models (designed to evaluate efficacy) as well as non-clinical safety assessment (toxicology and safety pharmacology) of therapeutic candidates.
- Directed the planning, execution, modeling and reporting of non-clinical (GLP) and clinical pharmacokinetics studies (bio-availability, distribution and metabolism).
- Development of short- and long-term strategic plans regarding capital investment, new technologies and services, and scientific staffing and facilities as they relate to the global department and the different locations.
- Developed and maintained client/sponsor relationships and serve as primary sponsor contact for pharmacology as well as non-clinical safety assessment studies.
- Responsible for overall coordination of study bids, study design/conduct, protocol review, consultant interactions, staffing needs, and analysis/reporting of pharmacokinetics as well as non-clinical safety assessment studies. Served as study director.
- In collaboration with other scientific staff, provided senior-level review of protocols, reports and related documents for appropriate scientific content and interpretation.
- Directed and supervised the following functional area: Pharmacology and Experimental Medicine, Metabolism and Pharmacokinetics, Safety Pharmacology and Preclinical Safety.
- Supervised a group of more than 150 employees, including 12 PhDs and DVMs.

### **Athersys, Cleveland, OH, USA**

*2004(Dec)-2006(Jan) Senior Director, Head of Pharmacology*

*2003(May)-2004(Dec) Director, Head of Pharmacology*

- Directed Pharmaceutical R&D for Metabolic Diseases, Oncology, CNS and Inflammation:
- Identified hit series and developed leads for the three targets (sub-nanomolar potencies)
- Optimized leads for pharmaceutical properties (DMPK, rodent, dog and primate)
- Evaluated leads for Efficacy and Safety (acute and chronic, rodent and dog)
- Moved two compounds in late stage preclinical evaluation (Safety and TOX, rodent, dog and primate)
- D.D.C. (Drug Development Candidate) status reached in May 2005 for ATX-105.
- Investigational New Drug submitted in 2006 and Phase I successfully completed in 2007.

- In charge of discovery pharmacology (*in vitro* and *in vivo*) from assay development to lead identification and optimization
- In charge of preclinical efficacy and safety studies (*in vitro* and *in vivo*; rodent, dogs and N.H.P.)
- In charge of pharmaceuticals (*in vitro* and *in vivo*) from drug disposition and metabolism to TOX evaluations (rodent, dogs and N.H.P.)
- Directing and managing the following groups: Cellular and Molecular Pharmacology, ADMET-DMPK, Efficacy and Safety Pharmacology to meet company executive goals
- Supervising a group of 18 employees including 4 senior PhD scientists

### **Millennium Pharmaceuticals, Cambridge, MA, USA**

2000 - 2003(April) *Senior Scientist, Head of In Vivo Pharmacology and Physiology*

- Planned, coordinated and directed all preclinical studies in the development of MLN4760
- Met aggressive timelines for the delivery of MLN4760 to Drug Development Candidate (D.D.C.) status (company and company's partner executive management review)
- Submitted physician-sponsored IND application to study MLN4760
- Designed and performed studies demonstrating the new therapeutic utility of company's proprietary products (Obesity and Diabetes)
- Coordinated all animal studies of drugs with company's partner
- Coordinated and established new research focus for one of the company's partner CNS product pipeline
- Directed and managed Pharmacology and Physiology Groups to meet company executive goals
- Supervised a group of 16 employees including 2 senior PhD scientists and 4 PhD scientists

1998-2000 *Scientist, Head of Metabolic Physiology*

- Planned, coordinated and directed studies of company's product on GI absorption of fatty acids *in vitro* and in animal models
- Planned, coordinated and directed studies of company's product on cancer wasting disorders *in vitro* and in animal models
- Designed and performed studies demonstrating the new therapeutic utility of company's proprietary product using genetically-engineered mice (knockout and transgenics)
- Designed and performed *in vivo* studies of new applications of company's genomics products
- Developed and validated animals models for obesity, nutrient absorption, eating and wasting disorders
- Designed and built the Metabolic Physiology Group
- Supervised a group of five employees, including 2 PhDs

### **Novartis AG, Basel, Switzerland**

1996-1998 *Lab-Head, Metabolic and Cardiovascular Diseases*

- Planned and coordinated preclinical studies in laboratory resulting in the development of CGP71683
- Established new research focus for company's neuropeptide Y antagonist program
- Developed and validated animals models for obesity, nutrient absorption and eating disorders
- Directed and managed *in vivo* Obesity and Pharmacokinetics Groups (rodent and N.H.P.) to meet project executive goals
- Developed *ex vivo* assay for pharmacodynamic studies
- Supervised 2 PhDs and 3 laboratory assistants

**Ciba-Geigy, Basel, Switzerland**

1995-1996 *Research Fellow, Metabolic and Cardiovascular Diseases*

- Designed and performed pilot studies of compounds on CV, CNS and neurocrine axis *ex vitro* and in animal models
- Developed and validated immunoassays for measuring circulating hormones
- Set up studies to examine the interactions of compounds with reproductive axis in rodents
- Initially supervised one laboratory assistant and a PhD student

**Boots Pharmaceuticals, Courbevoie, France****INSERM U308, Nancy, France**

1993 - 1995 *Postdoctoral Fellow*

- Designed and performed preclinical animal studies demonstrating the new therapeutic utility of BTS 54524 (sibutramine, now marketed as Meridia, US and Reductil, Europe)
- Designed and performed efficacy animal studies demonstrating the CNS profile of peptidic neuropeptide antagonists and agonist
- Performed the statistical validation of the Dutch Eating Behavior Questionnaire in a French population (clinical assessment of eating disorders)
- Supervised undergraduate students and one laboratory assistant

**ACADAMIC DISTINCTIONS:**

Society for the Study of Ingestive Behavior's

**Young Investigator Award**

Princeton University 1992

Society for the Study of Ingestive Behavior

International Association for the Study of Obesity's

**International Young Investigator Competition Award**

Toronto 1994

International Association for the Study of Obesity

**PATENTS:**

Stricker-Krongrad A and Wei G.

USP 6,197,530 GPR10 as a target for identifying weight modulating compounds.

Acton S, et al. and Stricker-Krongrad A.

WO 02/39997 ACE-2 modulating compounds and methods of use thereof

White DW, et al. and Stricker-Krongrad A.

WO 02/074905 Leptin induced genes

Tartaglia LA and Stricker-Krongrad A.

USPA 20030053951 Use of non-invasive imaging technologies to monitor in vivo gene-expression

Stricker-Krongrad A and Wei G.

USPA 20030096785 Control of hunger, satiety and food intake by modulating expression and activity of cephalic G protein-coupled receptors

## PUBLICATIONS:

Beck B., Stricker-Krongrad A., Nicolas J.P., Burlet C.

Chronic and continuous ICV infusion of neuropeptide Y disrupts the nycthemeral feeding patterns in rats.

Ann. N.Y. Acad. Sci. 1990, 611, 491-494.

Beck B., Stricker-Krongrad A., Burlet A., Nicolas J.P., Burlet C.

Influence of diet composition on food intake and hypothalamic neuropeptide Y (NPY) in the rat. Neuropeptides 1990, 17, 197-203

Beck B., Stricker-Krongrad A., Burlet A., Nicolas J.P., Burlet C.

Changes in hypothalamic neurotensin concentrations and food intake in rats fed a high fat diet. Int. J. Obesity 1992, 16, 361-366

Beck B., Stricker-Krongrad A., Nicolas J.P., Burlet C.

Chronic and continuous intracerebroventricular infusion of neuropeptide Y in Long-Evans rats mimics the feeding behavior of obese Zucker rats.

Int. J. Obesity 1992, 16, 295-302

Beck B., Stricker-Krongrad A., Burlet A., Nicolas J.P., Burlet C.

Specific hypothalamic neuropeptide Y variation with diet parameters in rats with food choice Neuroreport 1992, 3, 571-574

Stricker-Krongrad A., Beck B., Nicolas J.P., Burlet C.

Central effects of monosodium glutamate on feeding behavior in adult Long-Evans rats. Pharmacol. Biochem. Behav. 1992, 43, 881-886

Stricker-Krongrad A., Beck B., Max J.P., Nicolas J.P., Burlet C.

Intracerebroventricular injection of monosodium-glutamate (MSG) stimulates food intake in Long Evans rats.

In "Obesity in Europe 1991" G. AILHAUD, B. GUY-GRAND, M. LAFONTAN, D. RICQUIER Eds., John Libbey (London), 1992, pp.51-54

Stricker-Krongrad A., Barbanel G., Beck B., Burlet A., Nicolas J.P., Burlet C.

K<sup>+</sup>- stimulated neuropeptide Y release into the paraventricular nucleus and relation to feeding behavior in free-moving rats.

Neuropeptides 1993, 24, 307-312

Stricker-Krongrad A., Beck B., Nicolas J.P., Burlet C.

The pros and cons in the use of intracerebral microdialysis and push-pull perfusion for harvesting heavy weight extracellular compounds : a study with neuropeptide Y.

Curr. Separations, 1993, 12, 78

Mertes P.M., Beck B., Jaboin Y., Stricker-Krongrad A., Carteaux J.P., Pinelli G., El Abassi K., Villemot J.P., Burlet C. Boulanger M.  
Microdialysis to estimate myocardial interstitial neuropeptide Y release.  
Reg. Pept., 1993, 49, 81-90.

Beck B., Stricker-Krongrad A., Burlet A., Nicolas J.P., Burlet C.  
Macronutrient type independently of energy intake modulates hypothalamic neuropeptide Y (NPY) in Long-Evans rats.  
Brain Res. Bull. , 1994, 34, 2, 85-91.

Stricker-Krongrad A., Max J.P., Musse N., Nicolas J.P., Burlet C, Beck B.  
Increased threshold concentrations of neuropeptide Y for a stimulatory effect on food intake in obese Zucker rats - changes in the microstructure of the feeding behavior.  
Brain Res., 1994, 660, 162-166.

Beck B., Stricker-Krongrad A., Musse N., Nicolas J.P., Burlet C.  
Putative neuropeptide Y antagonist failed to decrease overeating in obese Zucker rats.  
Neurosci. Letters, 1994, 181, 126-128.

Stricker-Krongrad A., Beck B., Burlet C.  
Microdialysis and push-pull perfusion to estimate hypothalamic paraventricular neuropeptide Y release.  
in Monitoring Molecules in Neuroscience, 1994 (A. Louilot, T. Durkin, U. Spampinato, M. Cador. Eds), 354-355.

Mertes P.M., El Abassi K., Beck B., Jaboin Y., Carteaux J.P., Pinelli G., Stricker-Krongrad A., Villemot J.P., Burlet C.  
Interstitial myocardial norepinephrine and neuropeptide Y release following coronary occlusion.  
in Monitoring Molecules in Neuroscience, 1994 (A. Louilot, T. Durkin, U. Spampinato, M. Cador. Eds), 352-353.

Stricker-Krongrad A., Beck B., Burlet C.  
Nitric oxide mediates hyperphagia of obese Zucker rats: relation to specific changes in the microstructure of feeding behavior.  
Life Sciences (Pharmacol. Letters), 1995, 58 (1), 9-15.

Stricker-Krongrad A., Beck B., Burlet C.  
Enhanced feeding response to neuropeptide Y in hypothalamic neuropeptide Y-depleted rats.  
Eur. J. Pharmacol., 1996, 295, 27-34.

Lluch A., Kahn J.P., Stricker-Krongrad A., Ziegler O., Droin P., Mejean L.  
Internal validation in French of the Dutch Eating Behavior Questionnaire.  
European Psychiatry, 1996, 11, 198-203.

Cusin I., Rhoner-Jeanrenaud F., Stricker-Krongrad A., Jeanrenaud B.  
Weight-reducing effect of intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats : reduced sensitivity compared to lean animals.

Diabetes, 1996, 45, 1446-1450.

Mejean L, Stricker-Krongrad A., Lluch A.  
Chronobiology, nutrition and metabolism.  
Pathologie et Biologie, 1996, 44, 603-609.

Mejean L, Stricker-Krongrad A., Lluch A.  
The endocrine system and diabetes.  
in Handbook of Experimental Pharmacology. Editors: P.H. Redfern and B. Lemmer, Springer-Verlag Berlin 1997, 125, Chapter 12, 333-350.

Beck B., Stricker-Krongrad A., Burlet A., Musse N., Nicolas J.P., Burlet C.  
Dietary preferences in monosodium glutamate-lesioned rats: age-variable influence of hypothalamic neuropeptide  
Neurosci. Letters, 1997, 225, 153-156.

Schaffhauser A., Stricker-Krongrad A., Brunner L., Cumin F., Gerald C., Whitebread S., Criscione L., Hofbauer K.G.  
Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides.  
Diabetes, 1997, 46, 1792-1798.

Lollmann B., Gruninger S., Stricker-Krongrad A., Chiesi M.  
Detection and quantification of the leptin receptor splice variants Ob-Ra, b and e in different mouse tissues.  
BBRC, 1997, 238, 648-652.

Brunner L., Nick Hp., Cumin F., Chiesi M., Baum Hp., Whitebread S., Stricker-Krongrad A., Levens N.  
Leptin is a physiologically important regulator of food intake.  
Int. J Obesity, 1997, 21, 1152-1160.

Stricker-Krongrad A., Kozak R., Beck B., Nicolas J.P., Burlet C.  
Physiological regulation of neuropeptide Y release in lean and obese Zucker rats.  
Am. J. Physiol., 1997, 273, 42, R2112-R216.

Beck B., Kozak R., Stricker-Krongrad A., Burlet C.  
Neuropeptide Y release in the paraventricular nucleus of Long-Evans rats treated with leptin.  
BBRC, 1998, 242, 636-639.

Stricker-Krongrad A., Burlet C, Beck B.  
Behavioral deficits in the monosodium glutamate rat: specific changes in the structure of feeding behavior.  
Life Sciences, 1998, 62, 2127-2132.

Stricker-Krongrad A., Burlet A., Nicolas J.P., Burlet C., Beck B.  
Neuropeptide Y in the ventromedial and suprachiasmatic nuclei and feeding pattern in monosodium glutamate-treated rats.



Nutr. Neurosci., 1998, 1, 183-189.

Wyss P., Levens N, Stricker-Krongrad A.

Stimulation of feeding in lean but not obese Zucker rats by a selective neuropeptide Y Y5 receptor agonist.

Neuroreport, 1998, 9, 2675-2677.

Stricker-Krongrad A., Burlet C, Beck B.

Hypothalamic neuropeptide Y and plasma leptin after long-term high-fat feeding in the rat.

Neuroscience Letters, 1998, 254(3):157-160.

Schaffhauser A., Whitebread S., Haener R., Hofbauer K.G., Stricker-Krongrad A.

Neuropeptide Y Y1 receptor antisense oligodeoxynucleotides enhance food intake in energy-deprived rats.

Regulatory Peptides, 1998, 75-6:417-423.

Wyss P., Stricker-Krongrad A., Brunner L., Crossthwaite A., Whitebread S., Criscione L.

The pharmacology of neuropeptide Y receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes.

Regulatory Peptides, 1998, 75-6:363-371.

Beck B., Stricker-Krongrad A., Richy S., Burlet C.

Evidence that hypothalamic neurotensin signals leptin effects on feeding behavior in normal and fat-preferring rats.

Biochemical & Biophysical Research Communications, 1998, 252(3):634-638.

Lubkin M., Stricker-Krongrad A.

Independent feeding and metabolic actions of orexins in mice.

Biochemical & Biophysical Research Communications, 1998, 253(2):241-245.

Criscione L., Rigollier P., Batzl-Hartmann C., Rueger H., Stricker-Krongrad A., Wyss P., Brunner L., Whitebread S., Yamaguchi Y., Gerald C., Heurich RO., Walker MW., Chiesi M., Schilling W., Hofbauer KG., Levens N.

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y-5 receptor.

Journal of Clinical Investigation, 1998, 102(12):2136-2145.

Zakrzewska KE., Cusin I., Stricker-Krongrad A., Boss O., Ricquier D., Jeanrenaud B., Rohner-Jeanrenaud F.

Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat.

Diabetes, 1999, 48(2):365-370.

Brunner L, Whitebread S, Leconte I, Stricker-Krongrad A., Cumin F, Chiesi M, Levens N.

A peptide leptin antagonist reduces food intake in rodents.

Int J Obes Relat Metab Disord. 1999 May;23(5):463-9.

Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe H, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB.  
Increased energy expenditure, decreased adiposity and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B (PTP-1B)-deficient mice.  
Mol Cell Biol. 2000 Aug;20(15):5479-89.

Schaffhauser AO, Stricker-Krongrad A, Hofbauer KG.  
NPY Y5 receptor subtype. Pharmacological characterization with antisense oligodeoxynucleotide screening strategy.  
Methods Mol Biol. 2000;153:129-50.

White DW, Zhou J, Stricker-Krongrad A, Ge P, Morgenstern JP, Dembski M, Tartaglia LA.  
Identification of leptin-induced transcripts in the mouse hypothalamus.  
Diabetes. 2000 Sep;49(9):1443-50.

Beck B, Stricker-Krongrad A, Burllet A, Cumin F, Burllet C.  
Plasma leptin and hypothalamic neuropeptide Y and galanin levels in Long-Evans rats with marked dietary preferences.  
Nutr. Neurosci. 2001, 4, 39-50.

Stricker-Krongrad A, Dimitrov T., Beck B.  
Central and peripheral dysregulation of melanin-concentrating hormone in obese Zucker rats.  
Mol. Brain Res. 2001, 92, 43-48.

Beck B, Richy S, Dimitrov T, Stricker-Krongrad A.  
Opposite regulation of hypothalamic orexin and neuropeptide Y receptors and peptide expressions in obese Zucker rats.  
Biochem Biophys Res Commun. 2001 Aug 24;286(3):518-23.

Stricker-Krongrad A, Richy S, Beck B.  
Orexins/hypocretins in the ob/ob mouse: hypothalamic gene expression, peptide content and metabolic effects.  
Regul Pept. 2002 Mar 15;104(1-3):11-20.

Beck B, Burllet A, Max JP, Stricker-Krongrad A.  
Effects of long-term ingestion of aspartame on hypothalamic neuropeptide Y, plasma leptin and body weight gain and composition.  
Physiol Behav. 2002 Feb 1-15;75(1-2):41-7.

Beck B, Musse N, Stricker-Krongrad A.  
Ghrelin, macronutrient intake and dietary preferences in long-evans rats.  
Biochem Biophys Res Commun. 2002 Apr 12;292(4):1031-5.

Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, Kim YB, Elmquist JK, Tartaglia LA, Kahn BB, Neel BG.  
PTP1B regulates leptin signal transduction in vivo.  
Dev Cell. 2002 Apr;2(4):489-95.

Ogier V, Ziegler O, Mejean L, Nicolas JP, Stricker-Krongrad A.

Obesity is associated with decreasing levels of the circulating soluble leptin receptor in humans. *Int J Obes Relat Metab Disord*. 2002 Apr;26(4):496-503.

Stricker-Krongrad A, Beck B.

Modulation of hypothalamic hypocretin/orexin mRNA expression by glucocorticoids. *Biochem Biophys Res Commun*. 2002 Aug;296(1):129-33.

Gimeno RE, Hirsch DJ, Punreddy S, Sun Y, Ortegon AM, Wu H, Daniels T, Stricker-Krongrad A, Lodish HF, Stahl A.

Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality. *J Biol Chem*. 2003 Dec 5;278(49):49512-6.

Beck B, Richy S, Stricker-Krongrad A.

Ghrelin and body weight regulation in the obese Zucker rat in relation to feeding state and dark/light cycle.

*Exp Biol Med (Maywood)*. 2003 Nov;228(10):1124-31.

Gu W, Geddes B, Zhang C, Foley K and Stricker-Krongrad A.

The prolactin-releasing peptide receptor (GPR10) regulates body weight homeostasis in mice. *J Mol Neurosci*. 2004 Feb-Apr;22(1-2):93-103.

Perreault M, Istrate N, Wang L, Tozzo S and Stricker-Krongrad A.

Resistance to the orexigenic effect of ghrelin in dietary-induced obesity in mice: reversal after weight loss.

*International Journal of Obesity*. 2004 July;28(7):879-885.

Kim JK, Gimeno RE, Higashimori T, Kim HJ, Choi H, Punreddy S, Mozell RL, Tan G, Stricker-Krongrad A, Hirsh DJ, Fillmore JJ, Liu ZX, Dong J, Cline G, Stahl A, Lodish HF and Schulman GI.

Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle.

*JCI*. 2004 March;113(5):756-763.

Beck B, Max JP, Richy S and Stricker-Krongrad A.

Feeding response to a potent prolactin-releasing peptide agonist in lean and obese Zucker rats. *Brain Res*. 2004 July;1016(1):135-138.

Babic A, Lai M, Wang H, Daniels T, Felbinger T, Burger P, Stricker-Krongrad A and Wagner D. Leukocyte adhesion through ICAM-1 and b2 integrin regulates fat oxidation and insulin clearance during fasting.

*Molecular Medicine* 2004 Dec 3

Beck B, Richy S, Stricker-Krongrad A.

Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats.

*Life Sci*. 2004 Dec 10;76(4):473-8.

Stricker-Krongrad A, Beck B.

Up-regulation of neuropeptide Y receptors in the hypothalamus of monosodium glutamate-lesioned Sprague-Dawley rats.

Nutr Neurosci. 2004 Aug;7(4):241-5.

Robarge MJ, Bom DC, Tumej LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ, Bennani YL.

Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1749-53.

Song J, Doucette C, Hanniford D, Hunady K, Wang N, Sherf B, Harrington JJ, Brunden KR, Stricker-Krongrad A.

Generation of cell lines for drug discovery through random activation of gene expression: application to the human histamine H3 receptor.

Assay Drug Dev Technol. 2005 Jun;3(3):309-18.

Anderson JT, Ting AE, Boozer S, Brunden KR, Crumrine C, Danzig J, Dent T, Faga L, Harrington JJ, Hodnick WF, Murphy SM, Pawlowski G, Perry R, Raber A, Rundlett SE, Stricker-Krongrad A, Wang J, Bennani YL.

Identification of novel and improved antimitotic agents derived from noscapine.

J Med Chem. 2005 Nov 17;48(23):7096-8.

Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J, Gill S, Gill R, Ting A, Sherf B, Brunden K, Stricker-Krongrad A.

Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.

J Pharmacol Toxicol Methods. 2006 Jul-Aug;54(1):42-55.

Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, Sherf B, Harrington J, Brunden K, Stricker-Krongrad A.

Development of homogeneous high-affinity agonist binding assays for 5-HT<sub>2</sub> receptor subtypes.

Assay Drug Dev Technol. 2005 Dec;3(6):649-59.

Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, Bennani YL.

The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT<sub>2C</sub> receptor agonists.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2891-4.

Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, Mozell RL, Byrnes JJ, Stricker-Krongrad A, Chou CJ, Tartaglia LA, Lodish HF, Stahl A, Gimeno RE.

Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity.

Gastroenterology. 2006 Apr;130(4):1259-69.

Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, Bennani YL.

The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT<sub>2C</sub> receptor agonist.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4130-4.

Beck B, Richy S and Stricker-Krongrad A.

Responsiveness of obese Zucker rats to [D-Trp<sup>34</sup>]-NPY supports the targeting of Y5 receptor for obesity treatment.

Nutr Neurosci. 2007 Oct-Dec;10(5-6):211-4.

Sani SN, Henry K, Böhlke M, Kim J, Stricker-Krongrad A, Maher TJ.

The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.

Cancer Chemother Pharmacol. 2010 May;66(1):159-69. Epub 2009 Oct 9

Tumey LN, Robarge MJ, Gleason E, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf B, Mays RW, Stricker-Krongrad A, Brunden KR, Bennani YL, Harrington JJ.

3-Indolyl sultams as selective CRTh<sub>2</sub> antagonists.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3287-90. Epub 2010 Apr 14.

Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, Stricker-Krongrad A, Song J, Doucette C, Murphy S, Bennani YL.

Investigation of 4-piperidinols as novel H<sub>3</sub> antagonists.

Bioorg Med Chem Lett. 2010 Nov 1;20(21):6246-9. Epub 2010 Aug 24.

Rabito CA, van Tongeren S, Zavorskas PA, Stricker-Krongrad A, Robb J, Hauptert GT Jr.

Measurement of glomerular filtration rate in anesthetized and conscious rhesus monkeys (*Macaca mulatta*).

Am J Vet Res. 2010 Dec;71(12):1492-9.

Braun A, Dofiles L, Rousselle S, Guerrero L, Gunther J, Yednock T, Stricker-Krongrad A, Messersmith E.

Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement.

PLoS One. 2010 Dec 13;5(12):e14314

## TRADE PUBLICATIONS:

Stricker-Krongrad A and Stephen Wilson.

Guarding the Heart.

Drug Discovery and Development. 2009 June; Vol 12 No 6: 26-28.

<http://www.dddmag.com/Article-Guarding-the-Heart-060109.aspx>

Stricker-Krongrad A and Stephen Wilson.  
Minimizing Cardiovascular Liabilities Throughout Drug Development.  
Drug Delivery Technologies. 2009 Oct; Vol 9 No 9: 77-79.  
<http://www.drugdeliverytech-online.com/drugdelivery/200910/>

Stricker-Krongrad A and Smith E.  
How to Ensure the Best Chance of Success for your Therapeutic Proteins Programs.  
Life Science Leader. Editorial of November 05 2009.  
<http://www.lifescienceleader.com>